Episode 835: Spruce Stock Has More Upside, How Rare Disease Drugs Stay Profitable, CAPR Short

In this episode, Martin explains why he believes Spruce stock still has room for further gains and discusses what makes rare disease drugs maintain profitability over time. He also outlines his short thesis on CAPR and the factors influencing that position.